🔎 Trials Near Me

Inicio › Mieloma múltiple › Wisconsin

Ensayos clínicos de Mieloma múltiple en Wisconsin

28 estudios sobre Mieloma múltiple buscan participantes en Wisconsin.

Ciudades en Wisconsin

Texto oficial del estudio (inglés)

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

  • Mayo Clinic Health System-Eau Claire Clinic, Eau Claire
  • Mayo Clinic Health System-Franciscan Healthcare, La Crosse
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06630104

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  • Research Site, Madison
  • Research Site, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07391657

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

  • University of Wisconsin Carbone Cancer Center, Madison
  • Medical College of Wisconsin, Milwaukee
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT04973605

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  • Medical College Of Wisconsin, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07258511

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  • Froedtert Memorial, Milwaukee
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05201781

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

  • The Medical College of Wisconsin, Milwaukee
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07116616

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Aurora Cancer Care - Burlington, Burlington
  • Aurora Health Care - Germantown Health Center, Germantown
  • Aurora Cancer Care - Grafton, Grafton
  • y 13 más
ReclutandoFase 2
Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Medical College of Wisconsin, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07648264

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  • Medical College of Wisconsin, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT06615479

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06297226

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

  • University of Wisconsin, Madison
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 31 ago 2026 · NCT07479979

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

  • Research Site, Milwaukee
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 ago 2026 · NCT07681596

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
  • University of Wisconsin Carbone Cancer Center-University Hospital, Madison
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT06152575

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • ThedaCare Regional Cancer Center, Appleton
  • Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton, Appleton
  • Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield, Brookfield
  • y 47 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT04566328

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

  • Gundersen Lutheran, La Crosse
ReclutandoFase 3
Edades de 18 a 79 · Todos los sexos · Actualizado el 17 ago 2026 · NCT07285239

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Milwaukee
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05850234

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

  • Froedtert & the Medical College of Wisconsin, Milwaukee
ReclutandoFase 1
Edades de 18 a 80 · Todos los sexos · Actualizado el 10 ago 2026 · NCT05976555

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  • University of Wisconsin - Carbone Cancer Center, Madison
  • MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT07284758

Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma

  • Medical College of Wisconsin, Milwaukee
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT07236502

Integrated Cancer Repository for Cancer Research

  • Bellin Memorial Hospital, Green Bay
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 19 a 110 · Todos los sexos · Actualizado el 29 jun 2026 · NCT02012699

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Langlade Hospital and Cancer Center, Antigo
  • ThedaCare Regional Cancer Center, Appleton
  • Duluth Clinic Ashland, Ashland
  • y 22 más
ReclutandoFase 3
Todas las edades · Todos los sexos · Actualizado el 10 jun 2026 · NCT05561387

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  • St Vincent HSHS (Green Bay Oncology), Green Bay
  • University of Wisconsin Hospital and Clinics, Madison
  • Froedtert Memorial Lutheran Hospital, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 jun 2026 · NCT05243797

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

  • University of Wisconsin Clinical Science Center, Madison
  • Medical College of Wisconsin, Milwaukee
ReclutandoFase 2
Edades de 19 en adelante · Todos los sexos · Actualizado el 4 jun 2026 · NCT06974786

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

  • Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 abr 2026 · NCT05862012

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

  • Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ene 2026 · NCT04240054

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

  • Froedtert & the Medical College of Wisconsin, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ene 2026 · NCT07093554

Long-term Follow-up Study of Patients Receiving CAR-T Cells

  • Froedtert Hospital & Medical College of Wisconsin, Milwaukee
ReclutandoEstudio observacional
Edades de 18 a 80 · Todos los sexos · Actualizado el 10 nov 2025 · NCT03375619

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

  • Froedtert and the Medical College of Wisconsin, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2025 · NCT05722418

De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.